Vitamin B2 (Riboflavin): Benefits, Dosage, and What the Research Says

Riboflavin - known as vitamin B2 - is one of eight water-soluble B vitamins and an essential micronutrient that humans must obtain from food or supplementation. First isolated in the early 1930s, it takes its name from ribose (its sugar component) and flavus, the Latin word for yellow, reflecting the vivid yellow-orange color it imparts to urine at higher doses.

Riboflavin is found naturally in a wide range of foods, with the richest sources being organ meats (beef liver), dairy products, eggs, lean meats, fish, and certain fortified cereals. Leafy greens such as spinach and broccoli also contribute meaningful amounts. Because riboflavin is degraded by UV light, milk stored in clear containers loses a significant fraction of its content within hours of light exposure.

Recommended Dietary Allowances

The U.S. Recommended Dietary Allowance (RDA) for adults is 1.3 mg/day for men and 1.1 mg/day for women. Requirements increase modestly during pregnancy (1.4 mg/day) and lactation (1.6 mg/day). Most adults who eat a varied diet meet the RDA without supplementation, though subpopulations - including the elderly, vegans, competitive athletes, and people with certain genetic variants - are at higher risk of subclinical deficiency.⁶

Signs of Deficiency

Clinical riboflavin deficiency (ariboflavinosis) is uncommon in high-income countries but manifests distinctly when it occurs. Hallmark signs include angular stomatitis (cracking at the corners of the mouth), cheilosis (cracked, inflamed lips), glossitis (swollen, magenta-colored tongue), seborrheic dermatitis around the nose and ears, and anemia with reduced red blood cell production. A 2023 review in the Annual Review of Nutrition noted that subclinical riboflavin insufficiency - detectable only by functional biomarkers such as the erythrocyte glutathione reductase activation coefficient (EGRAC) - may be surprisingly prevalent even in wealthy nations, yet remains largely undetected because riboflavin biomarkers are rarely measured in routine clinical practice.⁶

After absorption in the small intestine, riboflavin is phosphorylated in most tissues to form flavin mononucleotide (FMN) and then further converted to flavin adenine dinucleotide (FAD). These two coenzymes are the biologically active forms of vitamin B2 and are incorporated into a class of proteins called flavoenzymes or flavoproteins.

Energy Metabolism and Mitochondrial Function

FAD and FMN act as reversible electron carriers - accepting electrons during oxidative reactions and donating them along the mitochondrial electron transport chain. FAD is an essential cofactor for succinate dehydrogenase (mitochondrial Complex II), which participates in both the citric acid cycle and the electron transport chain, enabling the synthesis of adenosine triphosphate (ATP). A 2016 review in Current Drug Targets described riboflavin as a biological precursor of FAD and FMN that are "essential for the structure and function of flavoproteins" underpinning mitochondrial energy metabolism.⁸ Defects in riboflavin transport or metabolism can cause measurable impairments in cellular energy production.

Antioxidant Defense via Glutathione

FAD is an obligate cofactor for glutathione reductase, the enzyme that regenerates reduced glutathione (GSH) from its oxidized form (GSSG). GSH is the most abundant intracellular antioxidant in human cells, neutralizing reactive oxygen species and protecting proteins, lipids, and DNA from oxidative damage. Without adequate riboflavin, glutathione reductase activity falls, compromising the body's primary antioxidant recycling system.¹⁰

Folate and Homocysteine Metabolism

Riboflavin (as FAD) is also the cofactor for methylenetetrahydrofolate reductase (MTHFR), a central enzyme in one-carbon metabolism that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate - the primary circulating form of folate used for homocysteine remethylation to methionine. People carrying the MTHFR C677T polymorphism produce a variant enzyme with reduced affinity for FAD, making them especially sensitive to riboflavin status. A 2023 Nordic Nutrition scoping review confirmed that riboflavin functions as a coenzyme in numerous metabolic pathways and that genetic factors are among the key determinants of individual riboflavin requirements.⁷

The most extensively researched clinical application of riboflavin supplementation is the support of healthy migraine frequency. Migraine is associated with impaired mitochondrial energy metabolism and oxidative stress in susceptible individuals, and researchers hypothesized that high-dose riboflavin might help normalize mitochondrial function in this population.

What the Research Shows

The foundational human study remains a randomized, placebo-controlled trial published in Neurology in 1998. Schoenen and colleagues assigned 55 adult migraine patients to 400 mg riboflavin per day or placebo for three months. Using a clinically meaningful threshold of at least 50% reduction in monthly attack frequency, 59% of riboflavin-treated patients responded versus only 15% of those on placebo, yielding a number-needed-to-treat of 2.3. The safety profile was excellent, with only minor events reported in both groups.¹

A 2026 systematic review and dose-response meta-analysis pooling 12 clinical trials and 749 participants found that riboflavin supplementation produced statistically significant reductions in both attack frequency (WMD: -1.39 attacks/month; 95% CI: -2.52 to -0.25) and headache duration (WMD: -1.36 hours; 95% CI: -2.69 to -0.03) compared with control groups. The dose-response analysis demonstrated a linear relationship between riboflavin intake and frequency reduction up to 400 mg/day, with no apparent plateau.² Migraine severity showed a favorable trend that did not reach statistical significance.

An earlier narrative review of 11 studies confirmed that supplementation in adults "can play a positive role in reducing the frequency and duration of migraine attacks with no serious side effects," while noting the evidence base in pediatric populations is more limited.³

Current Guidance

Several neurology societies - including the American Headache Society - include riboflavin among first-line nutraceutical options for migraine prophylaxis. The typical studied dose is 400 mg/day taken with food, continued for at least 3 months before evaluating response. It is important to work with a healthcare provider when adding any supplement to a migraine management plan.

Approximately 10-15% of people of Northern European ancestry carry the MTHFR 677TT homozygous genotype. Because this variant enzyme has a reduced affinity for its FAD cofactor, it is less active under conditions of low riboflavin status. The clinical consequences include elevated plasma homocysteine, which is recognized as an independent marker of cardiovascular risk, as well as impaired blood pressure regulation in some individuals.

What the Research Shows

A cross-sectional study of 423 healthy blood donors found that plasma riboflavin was an independent predictor of total homocysteine after adjusting for age, sex, folate, cobalamin, and MTHFR genotype. Homocysteine concentrations were 1.4 micromol/L higher in the lowest compared with the highest riboflavin quartile (P = 0.008), and critically, this relationship "was essentially confined to subjects with the C677T transition" in MTHFR - individuals with the TT genotype.⁵

A targeted randomized controlled trial enrolled 91 hypertensive patients who had been confirmed to carry the MTHFR 677TT genotype and who were already receiving antihypertensive medications. After 16 weeks of supplementation with only 1.6 mg/day riboflavin (just above the RDA), the riboflavin group showed an overall treatment effect of 5.6 +/- 2.6 mmHg reduction in systolic blood pressure compared with placebo (141.8 to 137.1 mmHg vs. 143.5 to 144.3 mmHg). This effect was independent of the number and type of antihypertensive drugs used by participants.⁴

What This Means for Supplementation

These findings suggest that riboflavin's role in cardiovascular health is largely genotype-specific. For individuals without the TT variant, adding extra riboflavin above the RDA is unlikely to produce measurable changes in homocysteine or blood pressure. For the minority who do carry this variant, even modest riboflavin repletion may help maintain homocysteine and blood pressure already within the normal range - a finding of potential public health significance given the polymorphism's prevalence worldwide. Genetic testing is available through many clinical and direct-to-consumer services to determine MTHFR status.

Beyond its structural role in flavoenzymes, riboflavin contributes to the body's antioxidant network in ways that are increasingly well characterized. As a review in the British Journal of Nutrition noted, riboflavin is "one of the neglected antioxidant nutrients" that may have an antioxidant action both independently and as an essential component of the glutathione redox cycle.¹⁰

What the Research Shows

Riboflavin's antioxidant activity operates through two main mechanisms. First, as the obligate cofactor for glutathione reductase, FAD-bound riboflavin enables regeneration of reduced glutathione (GSH) from its oxidized dimer (GSSG), sustaining the body's primary intracellular antioxidant pool. Second, riboflavin itself can be oxidized directly, cycling between reduced and oxidized forms to quench free radicals - particularly in protecting against lipid peroxidation and reperfusion-related oxidative injury.¹⁰

A 2022 updated review in the British Journal of Nutrition confirmed riboflavin's antioxidant properties and concluded that it "helps reduce oxidative stress" through these mechanisms, while noting that clinical evidence in healthy populations is mechanistically sound but that further investigation is needed to quantify the magnitude of benefit in specific disease contexts.⁹ A comprehensive 2017 review identified riboflavin's emerging role in conditions involving elevated oxidative burden, including anemia, hypertension, diabetes, and neurodegenerative processes.¹²

Eye Health: A Note of Caution

Riboflavin's role in regenerating GSH in the lens of the eye has led to research interest in its relationship with cataracts. Because the lens is particularly vulnerable to oxidative damage, inadequate riboflavin status may impair lens protection. Evidence from observational studies is suggestive but mixed, and no definitive causal claim is supported by current data. The relationship warrants continued research.